![New patent expiration for Glaxosmithkline drug ARNUITY ELLIPTA – DrugPatentWatch - Make Better Decisions New patent expiration for Glaxosmithkline drug ARNUITY ELLIPTA – DrugPatentWatch - Make Better Decisions](https://i0.wp.com/www.drugpatentwatch.com/p/graph/s/t/ARNUITY+ELLIPTA-patent-expirations.png?ssl=1)
New patent expiration for Glaxosmithkline drug ARNUITY ELLIPTA – DrugPatentWatch - Make Better Decisions
![The Ellipta® in asthma and chronic obstructive pulmonary disease: device characteristics and patient acceptability | Therapeutic Delivery The Ellipta® in asthma and chronic obstructive pulmonary disease: device characteristics and patient acceptability | Therapeutic Delivery](https://www.future-science.com/cms/10.4155/tde-2017-0103/asset/images/medium/figure2.gif)
The Ellipta® in asthma and chronic obstructive pulmonary disease: device characteristics and patient acceptability | Therapeutic Delivery
![Arnuity ellipta and Breo ellipta drug interactions, a phase IV clinical study of FDA data - eHealthMe Arnuity ellipta and Breo ellipta drug interactions, a phase IV clinical study of FDA data - eHealthMe](https://www.ehealthme.com/static/img/graphs/drug-interaction/arnuity%20ellipta/breo%20ellipta/arnuity-ellipta-and-breo-ellipta-drug-interactions.png)
Arnuity ellipta and Breo ellipta drug interactions, a phase IV clinical study of FDA data - eHealthMe
![Inhalers! This is a follow-up from one of last weeks posts about the triple inhaler. We have 5 total inhalers that are … | Inhaler, Nebulizers, Combination therapy Inhalers! This is a follow-up from one of last weeks posts about the triple inhaler. We have 5 total inhalers that are … | Inhaler, Nebulizers, Combination therapy](https://i.pinimg.com/1200x/ea/ed/5f/eaed5fda66fdba0cfbfbab28d8c0ee08.jpg)